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The present review focuses on the numerous experimental models used to study the complexity of hepatic ischemia/reperfusion
(I/R) injury. Although experimental models of hepatic I/R injury represent a compromise between the clinical reality and
experimental simpliﬁcation, the clinical transfer of experimental results is problematic because of anatomical and physiological
diﬀerences and the inevitable simpliﬁcation of experimental work. In this review, the strengths and limitations of the various
models of hepatic I/R are discussed. Several strategies to protect the liver from I/R injury have been developed in animal models
and,someofthese,mightﬁndtheirwayintoclinicalpractice.Wealsoattempttohighlightthefactthatthemechanismsresponsible
for hepatic I/R injury depend on the experimental model used, and therefore the therapeutic strategies also diﬀer according to the
model used. Thus, the choice of model must therefore be adapted to the clinical question being answered.
1.Introduction
Ischemia-reperfusion (I/R) injury is a phenomenon in which
cellular damage in a hypoxic organ is accentuated following
the restoration of oxygen delivery [1–3]. In the liver, this
form of injury was recognized as a clinically important
pathological disorder by Toledo-Pereyra et al. in 1975 during
studies of experimental liver transplantation (LT). However,
it was not until the mid-1980s that the term reperfusion
injury was generally used in the literature on LT [2]. I/R
injury is an important cause of liver damage occurring
during surgical procedures including hepatic resections and
LT [4–6]. The shortage of organs has led centers to expand
theircriteriafortheacceptanceofmarginalgraftsthatexhibit
poor tolerance to I/R [7]. Some of these include the use of
organs from older donors and grafts such as small-for-size or
steatotic livers. However, I/R injury is the underlying cause
of graft dysfunction in marginal organs [7]. Indeed, the use
of steatotic livers for transplantation is associated with an
increased risk of primary nonfunction or dysfunction after
surgery[8].Inaddition,theoccurrenceofpostoperativeliver
failure after hepatic resection in a steatotic liver exposed to
normothermic ischemia has been reported [9]. Therefore,
minimizing the adverse eﬀects of I/R injury could improve
outcomes in steatotic liver surgery, increasing the number of
patients who successfully recover from major liver surgery.
AnimalmodelsofcoldandwarmhepaticI/Rarevaluable
tools for understanding the physiopathology of hepatic I/R
injury and discovering novel therapeutic targets and drugs.
Some of the mechanisms and cell types involved in hepatic
I/R injury are described below.
Thelackofoxygeninhepatocytesduringischemiacauses
ATP depletion and alterations in H+,N a +,a n dC a 2+ home-
ostasis that activate hydrolytic enzymes and impair cell vol-
umeregulationleadingtotheswellingofsinusoidalendothe-
lial cells (SECs) and Kupﬀer cells (KCs) [10]. This fact,
together with the imbalance between nitric oxide (NO) and
endothelin production, contributes to the narrowing of the2 Journal of Biomedicine and Biotechnology
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Figure 1: Mechanisms involved in hepatic ischemia-reperfusion injury. EC, endothelial cell; ET, endothelin; UPR/ER, unfolded protein
response/endoplasmic reticulum; IRE1, inositol-requiring enzyme 1; PERK, PKR-like ER kinase; SLP, secretory leukocyte protease inhibitor;
ICAM, intracellular cell adhesion molecule; VCAM, vascular cell adhesion molecule; GM-CSF, granulocyte-macrophage colony-stimulating
factor; IL, interleukin; INF, interferon; TNF, tumor necrosis factor; PAF, platelet-activating factor; LTB4, leucotriene B4; KC, Kupﬀer cell;
X/XOD, xanthine/xanthine oxidase; Cyt c: cytochrome c.
sinusoidal lumen and thus to microcirculatory dysfunction
(Figure 1). Capillary narrowing also contributes to hepatic
neutrophil accumulation [11]. Concomitantly, the activation
of KCs releases reactive oxygen species (ROS) and proin-
ﬂammatory cytokines, including tumour necrosis factor-
alpha (TNF-α) and interleukin-1 (IL-1) [12]. Similar to their
production in KCs, ROS can derive from mitochondria and
the xanthine dehydrogenase/xanthine oxidase (XDH/XOD)
pathway in activated SEC and hepatocytes. Cytokines release
through the induction of adhesion molecules (intercel-
lular cell adhesion molecule and vascular cell adhesion
molecule), and chemokines promote neutrophil activation
andaccumulation,therebycontributingtotheprogressionof
parenchymalinjurybyreleasingROSandproteases[1,3,12].
In addition, IL-1 and TNF-α recruit and activate CD4+
T lymphocytes, which produce granulocyte-macrophage
colony-stimulating factor, interferon gamma and TNF-β
(Figure 1).ThesecytokinesamplifyKCactivationandTNF-α
and IL-1 secretion and promote neutrophil recruitment and
adherenceintotheliversinusoids[13, 14].Platelet-activating
factor can prime neutrophils for superoxide generation,
whereas leukotriene B4 contributes to the ampliﬁcation of
the neutrophil response [1, 3].
2. ExperimentalModels
The speed of human studies is slow, the majority of human
tissues are not routinely accessible for research purposes,
and there is a very limited opportunity for interventional
studies. Although scientiﬁc research has always relied on the
use of cell cultures, information that is obtained through in
vitro studies can be extrapolated to biomedical research only
when analyzed within a complex organism with metabolic
functioning. Therefore, one avenue holding tremendous
potential in the search for therapies against I/R damage is
the use of intact living systems, in which complex biological
processes can be examined. There are many advantages of
animalstudies:largenumbersofanimals(especiallyrodents)Journal of Biomedicine and Biotechnology 3
can be bred and studied, interventional studies can be
performed, and established and emerging tools for targeted
manipulation of gene expression levels provide insight into
the function of mediators in hepatic I/R injury.
Comparison of the results of animal studies and their ex-
trapolation to human beings is feasible, but with limitations.
Among the primary obstacles are diﬀerences in hypothermia
and ischemia tolerance, diﬀerences in the anatomy of the
livers of various species and subspecies, diﬀerences between
and within the experimental models used, and diﬀerences
in the modes of administration, dosage, and metabolic
breakdown of the drugs under investigation. Thus, it is very
important to choose theanimalspeciesand theexperimental
model and to standardize the protocol according to the
clinical question under study.
2.1. Choice of the Animal Model. The species used for exper-
imental investigation of hepatic I/R injury range from mice
to pigs. Small animals such as mice and rats are exceptionally
useful because they are easy to manage, present minimal
logistical, ﬁnancial, or ethical problems, and provide the
potential for genetic alterations (e.g., transgenic and knock-
out animals). However, an important drawback is that the
results of studies performed in small animals are of limited
applicability to human beings due to their varying size
and anatomy of the liver and their faster metabolism [15].
Large animals such as pigs, sheep, and dogs exhibit greater
similarity in their anatomy and physiology to human beings.
Thus, they are more suited for the study of problems of
direct clinical relevance. However, their use is restricted by
seriouslogisticalandﬁnancialdiﬃcultiesandoftenbyethical
concerns. Furthermore, the technical possibilities of blood
and tissue processing are extremely restricted because of the
limited availability of immunological tools for use in large
animal species [15].
When selecting an animal species, the age and sex of the
animals should be considered. Depending on the duration of
ischemia, young (35–50g) and older rats (250–400g) exhibit
signiﬁcant diﬀerences in their hepatic microcirculation [16].
A mature rat weighing more than 250g (14–16 weeks old) is
the most suitable because younger rats can present technical
problems, whereas older rats are more prone to respiratory
infections and fat accumulation. Sex selection also aﬀects
experimentalresults,ashormonelevelsinfemaleanimalsare
dependent on the estrous cycle, which certainly aﬀects the
ischemia tolerance of the liver. For instance, a study demon-
strated that after normothermic liver ischemia, male rats
werelesssensitivetoreperfusioninjurythanfemalerats[17].
Considering the relevancy of hepatic steatosis in surgery,
experimental models of hepatic I/R injury in the presence
of steatosis have been developed. However, the mechanisms
involved in hepatic I/R injury, as it will be described in
following sections, are diﬀerent depending on the method
used to induce steatosis. The diﬀerent models of steatosis
include (1) induced genetic models such as db/db and
ob/ob mice and fa/fa rats, (2) animals fed diets with high
levels of saturated fat and/or carbohydrates and/or proteins,
(3) animals fed diets deﬁcient in methyl groups (choline,
methionine, folates), and (4) animals fed modiﬁed high-fat
diets (lower methionine and choline and higher-fat content)
[18].
2.2. Standardization of the Experiment. The induction of I/R
injury must be performed under standardized experimental
conditions. Of primary importance are the conditions under
which the animals are kept such as adequate acclimatization
time, maintenance under climatized conditions with 12h
light/12h darkness, and standardized diets. The anesthetic
method and postoperative analgesic regimen must also be
standardized. When choosing the anesthetic and analgesic
procedures, possible interactions withliver metabolism must
be considered. Attention must be paid to adequate monitor-
ing of blood pressure, heart rate, and body temperature.
3.NormothermicIschemia
3.1. Global Hepatic Ischemia with Portocaval Decompression.
The model of global liver ischemia with portal decompres-
sion ideally simulates the clinical situation of warm ischemia
after the Pringle maneuver for liver resection and LT. The
ﬁrst successful shunt operation in humans was performed
by Vidal in 1903 [19]. Blakemore was one of the ﬁrst
workers to report successful portal-systemic anastomosis in
rats working principally with endothelium-lined tubes [20].
Burnett et al. modiﬁed this technique to form a portocaval
shunt [21]. In 1959 Bernstein and Cheiker developed the
portosystemic shunt that conducted the portal blood after
functional hepatectomy into one of the iliac veins [22]. In
small animals, in addition to many other shunt techniques
such as the portofemoral shunt and the mesentericocaval
shunt via the jugular vein, in 1995, Spiegel et al. developed
the splenocaval shunt [23]( Figure 2). In large animals,
on the contrary, a portofemorojugular bypass is frequently
employed [24].
3.2. Global Liver Ischemia with Spleen Transposition. Beng-
mark et al. developed this model in 1970 for the surgical
treatment of portal hypertension [25]. In 1981 Meredith and
Wade presented a rat model that by transposition of the
spleen produced a portosystemic shunt in the anhepatic rat
[26]. A small incision is made in the left hypochondrium.
After transposition of the spleen into a subcutaneous pouch,
adequate portosystemic anastomoses arise after 2-3 weeks
(Figure 3). Reversal of blood ﬂow in the splenic vein,
induced by the transposition, stimulates angiogenesis. In the
second step 2 weeks later, the surgeon performs a median
laparotomy and temporary occlusion of the hepatoduodenal
ligament. This decompression by spleen transposition does
not require microsurgical technique and is therefore easy to
perform[27].Two-to-threeweekspostoperatively,thespleen
will have been encapsulated without any signs of bleeding or
inﬂammation (Figure 3). One disadvantage of this model is
the long time lapse (3 weeks) until the formation of adequate
portosystemic collaterals. Not until this point in time are
the collaterals suﬃciently large to take over portal vein ﬂow4 Journal of Biomedicine and Biotechnology
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Figure 2: Models of global normothermic liver ischemia. (a) Pringle maneuver. (b) Splecnocaval shunt. (c) Portojugular shunt. (d) Spleen
transposition.
completely. Furthermore, it is uncertain how the changes in
hepatic inﬂow will react upon the collaterals [28].
3.3. Partial Liver Ischemia. In 1982, Yamauchi et al. and
Hasselgren et al. described a model of hepatic ischemia
[29, 30]. In this technique, ischemia is induced by occlusion
of the hepatic artery, the portal vein, and the bile duct of
the left and median lobes. An extracorporeal shunt is not
necessary because blood ﬂow continues through the right
and caudal liver lobes. This model of 70% partial ischemia
has been widely used in experimental studies of hepatic I/R
[31, 32]. Additionally, a experimental model of 30% partial
liver ischemia has been used in which blood supply to the
right lobe of the liver is interrupted by occlusion at the level
of the hepatic artery and portal vein [11, 33].
It is known that, in clinical situations, partial hepate-
ctomy under I/R is usually performed to control bleeding
during parenchymal dissection. Therefore, the use of a
experimental model including both hepatic regeneration
and I/R injury is advisable to simulate the clinical situation
of selective or hemihepatic vascular occlusion for liver
resections. In experimental model, after resection of left
hepatic lobe, a microvascular clamp is placed across the
portal triad supplying the median lobe (30%). Congestion
of the bowel is avoided during the clamping period by
preserving the portal ﬂow through the right and caudate
lobes. At the end of ischemia time, the right lobe and
caudate lobes are resected, and reperfusion of the median
lobeisachievedbyreleasingtheclamp.Thismodelofhepatic
resectiondoesnotrequireanyportaldecompressionandalsoJournal of Biomedicine and Biotechnology 5
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Figure 3: (a) Transposition of the spleen to the subcutaneous tissue in the left hypochondrium. (b) Abdominal cavity after three weeks
of the transposition of the spleen. (c) Anhepatic phase in recipient with SPS. No intestinal congestion is observed secondary to clamping
of diﬀerent vessels. (d) Anhepatic phase in recipient without SPS. Intestinal congestion is observed secondary to clamping of the diﬀerent
vessels.
fulﬁlls certain important criteria such as reversibility, good
reproducibility, and simple performance [34, 35].
4. LiverTransplantation
LT in larger laboratory animals such as dogs and pigs is
technically easier. However, the rat has become the most
important subject for experimental LT because of, among
other factors, the availability of genetically deﬁned animals
[36].
Orthotopic liver transplantation (OLT) is a common yet
complex microsurgical technique. OLT in mice is technically
very diﬃcult, even without reconstruction of the hepatic
artery. By contrast, OLT in rats is technically accessible,
producing more clinically relevant and reliable data [37].
The development of clinically relevant OLT models in rats
[37] has advanced clinical knowledge in LT. These experi-
mental models facilitate the study of new preservation
methods, tolerance induction, rejection mechanisms, and
novel immunosuppressor therapies [38].
OLT in rats was ﬁrst reported in 1973 using hand-suture
techniques [39], and a modiﬁed model without hepatic
arteryreconstructionandtemporalshuntoftheportojugular
venovenous bypass was documented in 1975 [40]. However,
these models were not widely used due to the prolonged
surgical time and technical demand. With the cuﬀ method
being introduced in 1979 by Kamada and Calne [41], OLT in
rats without hepatic artery reconstruction became globally
accepted [37].
The donor operation, including the harvesting and
preparation of the donor liver, is usually performed accord-
ing to the procedure described by Kamada and Calne [41].
After arterial and portal perfusion, the suprahepatic vena
cava is dissected free from the diaphragmatic ring, and
the intrathoracic vena cava is transected. The aorta is cut
around the celiac axis to form the aortic patch. Finally, the
inferior vena cava, the portal vein, and the bile duct are cut,
and the graft is placed in a cold preservation solution [42]
(Figure 4). OLT is then performed by suture or mechanical
microvascular anastomoses. Sutured vascular anastomosis
reduces the incidence of thrombosis but takes a long time to
perform. Suprahepatic vena cava anastomosis is performed
by the continuous suturing technique. Then, portal vein
and infrahepatic vena cava anastomosis is performed in
the same manner. Hepatic artery reconstruction in rat LT
can prevent bile duct ischemia and preserve the structure
of the liver [43]. Several techniques of rearterialization by
suture have been proposed [42, 43], the best being the aortic
segment anastomosis technique [42]. After rearterialization,6 Journal of Biomedicine and Biotechnology
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Figure 4: Liver transplantation procedure. (a) Suprahepatic cava vein prepared for the anastomosis. (b) Inferior vein cava cuﬀ attachment.
(c)Anhepaticphaseintherecipientrat.(d)Anastomosisofsuprahepaticcavaveinbycontinuoussuture.(e)Portalveinanastomosisthrough
the cuﬀ method. (f) Anastomosis of the bile duct.
the common bile duct is anastomosed. OLT by hand-sewn
microanastomosis is a very useful method because this
technique comes closest to the techniques used in human
transplantation surgery [42]. Alternatively, livers can be
satisfactorily allografted in rats by using the rapid cuﬀ-
ligature technique for anastomosis [41, 42]. In the simpliﬁed
technique, the donor hepatic artery can be ligated because
it will not be anastomosed [38]. A mechanical microvascular
anastomosisforOLTintheratusingaquick-linkertechnique
that signiﬁcantly reduces the warm ischaemia time has
recently been proposed [44].
In an attempt to expand the size of the donor pool, a
number of surgical techniques have been developed over the
past 15 years, including split LT and living donor LT [45].
One of the beneﬁts of reduced-size grafts from living donors
is a graft of good quality with a short ischemic time, this
latter being possible because live donor procurements can be
electivelytimed withtherecipient procedure.Conversely, the
major concern over the application of living-related LT for
adults is graft-size disparity. Small grafts require posterior
regeneration to restore the liver/body ratio. It is well
known that I/R signiﬁcantly reduces liver regeneration after
hepatectomy [46]. Thus, the identiﬁcation and subsequent
modulation of mechanism that are involved in liver injury
and regeneration might favor the recovery and functioning
of the transplanted organ.Journal of Biomedicine and Biotechnology 7
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Figure 5: Illustrative representation of machine reperfusion.
To mimic some of the pathophysiological events that
occur during such clinical situations, several experimen-
tal models of reduced-size LT have been developed. For
example, OLT with the implantation of liver grafts that
approximated 30%–70% of the normal mass of a rat liver
has been performed. Graft size is important for normal
liver function and host survival [45]. It has been reported
that 100% of recipient rats that were implanted with 40%,
50%, 60%, or 70% of the liver survived regardless of the
duration of preservation. This suggests that graft sizes of
40% or greater are suﬃcient to meet the metabolic demands
of the recipients. The transplantation of a graft of 30%
of the normal liver mass provides an extreme model of
hepatic reduction that presumably stimulated a maximal
regenerative response [45].
Three possibilities exist with respect to the timing of
the graft reduction: in the donor before perfusion, in the
container (ex situ), or in the recipient after reperfusion. If the
reduction is done in vivo prior to the removal of the donor
liver, then two concerns exist (1) excessive bleeding might
stimulate systemic responses that could alter the liver and
(2) the immediate phase of the regeneration response could
be initiated in the donor animal. The second choice, ex situ
reduction,canbedonewithouttheriskofdamagingthegraft
by manipulation or aﬀecting anastomosis after reperfusion.
Finally, resection of the graft after implantation in the
recipient adds surgical stress and the risk of bleeding [47].
5. Optimizingthe Graft
5.1. Static Organ Preservation. The introduction of the
University of Wisconsin (UW) solution by Belzer and
Southard for static cold storage was a breakthrough and
remainstheconventionalmethodofpreservation.Reduction
of metabolic activity (by cooling) is the major principle of
organ preservation [48, 49]. Using this method, however,
organs undergo injury at several consecutive stages: warm
ischemia prior to preservation, cold preservation injury,
ischemic rewarming during surgical implantation, and repe-
rfusion injury [49]. Only a few studies have demonstrated
the optimization of graft function and survival with modiﬁ-
cation of static preservation. It is doubtful that considerable
improvements in organ preservation and especially in the
rescue of marginal organs will be possible as long as the
strategy is based on static principles [48]. The improvements
in UW preservation solution are summarized in Table 1.
5.2.MachinePerfusion. Machineliverperfusionhasemerged
with promising data over the past decade because it has
signiﬁcant potential in graft preservation and even more
potential in graft optimization when the use of marginal
organs is the objective.
Compared with simple cold storage (SCS), machine per-
fusion (Figure 5) confers many anticipated advantages such
as the following: (1) provision of continuous circulation and
better preservation of the microcirculation, (2) continuous
nutrient and oxygen delivery to fulﬁll the organ’s metabolic
demands, (3) removal of metabolic waste products and
toxins,(4)opportunitytoassessorganviability,(5)improved
clinical outcomes via improved immediate graft function
rates, (6) prolonged preservation time without increased
preservation damage, (7) administration of cytoprotective
and immunomodulating substances, and (8) lower graft
dysfunctionincidence,shorterhospitalstays,andbettergraft
survival rates [50].
5.3. Normothermic Machine Perfusion. Normothermic ma-
chine perfusion (NMP) maintains and mimics normal in
vivo liver conditions and function during the entire period
of preservation, thus avoiding hypothermia and hypoxia and
minimizing preservation injury [48, 50].
Sch¨ on et al. [51] studied NMP to preserve pig livers for
transplantation and to rescue them from warm ischemia in
a model of donor after cardiac death (DCD). Short (5h)
or prolonged (20h) NMP preservation is superior to SCS8 Journal of Biomedicine and Biotechnology
Table 1: Pharmacological treatments to protect liver against ischemia/reperfusion. AMP; activated protein kinase, AMPK; heme oxygenase-
1, HO-1; interleukin, IL; nitric oxide, NO; peroxisome proliferator-activated receptor-α,P P A R - α; peroxisome proliferator-activated receptor
(PPAR) γ,P P A R - γ; reactive oxygen species, ROS; tumour necrosis factor TNF;. xanthine dehydrogenase/xanthine oxidase, XDH/XOD.
Pharmacological therapy
Liver transplantation and warm hepatic ischemia
Drug Specie Experimental model Ischemic
time Eﬀect
Chlorpromazine (Ca2+
channel antagonist) Rat Liver transplantation 24h
↑ ATP, ↓ mitochondrial dysfunction and
alterations in lipid metabolism
Tauroursodeoxy-cholate Rat Liver transplantation 8h
↓ Endoplasmic reticulum stress
Warm ischemia +
hepatectomy 1h
Cbz-Val-Phe methyl ester
(calpain inhibitor) Rat Liver transplantation 24, 40h ↓ Calpain activation and SEC apoptotic
Tocopherol (antioxidant) Rat Liver transplantation 5h ↓ Lipid peroxidation, ↓ SEC damage and
microcirculatory disturbances Warm ischemia 45, 90min
Glutathione (antioxidant) Rat Warm ischemia 60, 90min ↓ Microcirculatory disturbances, ↑
detoxiﬁcation of ROS, Liver transplantation 24h
SOD (antioxidant) Rat Warm ischemia 45min
and 1h
↓ Microcirculatory disturbances and
leukocyte accumulation
Liver transplantation 8h
Allopurinol (XOD
inhibitor)
Rat,
Mice
Liver transplantation 8, 16h
↓ Oxidative stress
Warm ischemia 30, 60min
Bucillamine (antioxidant) Rat Liver transplantation 24h ↓ Oxidative stress
AMPK activators Rat Warm ischemia 90min ↑ NO, and ATP
Adenosine Rat Warm ischemia 90min ↑ NO
N-acetylcysteine
(glutathione precursor) Rat Liver transplantation 24h ↓ Microcirculatory disturbances
L-arginine (NO precursor) Rat Liver transplantation 18h
↑ ATP, ↑ NO, ↓neutrophil accumulation
Warm ischemia 45min
Spermine NONOate (NO
donor) Rat Warm ischemia 60, 90min ↓ IL-1α and oxidative stress
FK 409 (NO donor) Rat Liver transplantation 80min ↓ SEC damage, ↓ IL-1 ↑ HSP, and IL-10
EHNA (adenosine
deaminase inhibitor) Rat Liver transplantation 24, 44h
↑ Interstitial adenosine, ↓ leukocytes
rolling and microcirculatory disturbances
CGS-21680 (adenosine A2
receptor agonist) Rat Liver transplantation 30h ↓ SEC killing, ↑ cAMP
Anti-TNF antiserum Rat Liver transplantation 6, 24h
↓ TNF and leukocyte accumulation
Warm ischemia 90min
FR167653 (IL-1β and
TNFα suppressor) Rat Liver transplantation 48h
↓ TNF and IL1-α and Kupﬀer cell
activation
IL-10 Rat Warm ischemia 60min ↓ IL-1 and oxidative stress
Anti-ICAM-1 Rat Liver transplantation 24h ↓ Adherence of leukocytes in
postsinusoidal venules Warm ischemia 1h
PSGL-1 (P-selectin blocker) Rat Liver transplantation 6h
↓ Neutrophil inﬁltration, ↓ INFγ,T N F α
and iNOS
CS1 peptides (FN-α4β1
interaction blocker) Rat Liver transplantation 4h
↓ Neutrophil and lymphocyte T
inﬁltration, ↓ TNFα and iNOS
sCR1 (complement
inhibitor) Rat Liver transplantation 24h
↓ Microcirculatory disturbances, ↓
leukocyte adhesion
Sodium ozagrel
(thromboxane synthase
inhibitor)
Pig Liver transplantation 8h ↓ ET-1
Glycine (Kupfer cell
modulator) Rat Liver transplantation 24h ↓ TNFα and neutrophil accumulationJournal of Biomedicine and Biotechnology 9
Table 1: Continued.
Pharmacological therapy
Liver transplantation and warm hepatic ischemia
Drug Specie Experimental model Ischemic
time Eﬀect
GdCl3 (Kupﬀer cell
blocker) Rat Liver transplantation 24h ↓ TNFα and neutrophil accumulation,
Z-DEVD-FMK (caspase 3
and 7 inhibitor) Rat Liver transplantation 16h
↓ Apoptosis, ↑ microvascular perfusion
and Bcl-2
Cobalt-protoporphyrin IX
(HO-1 inducer) Rat Liver transplantation 6h ↓ T-cell and macrophages inﬁltration
ANP (vasodilating peptide) Rat Liver transplantation 24h ↓ Apoptosis, ↑ PI3K/Akt
Hemin (HO-1 inducer) Rat Liver transplantation 6h ↑ Bcl-2
Cerulenin (fatty acid
synthase inhibitor) Mice Warm ischemia 15min
↓ UCP2, ↑ ATP
Liver transplantation 80min
Doxorubicin (heat shock
proteins inducer) Rat Liver transplantation 48h ↓ TNFα, MIP-2 and NFκB
Catalase and derivatives Mice Warm ischemia 30min ↓ Oxidative stress
Rosiglitazone (PPAR-α
agonist) Rat Warm ischemia 30, 60,
90min
↑ Autophagy, ↓ cytokines
Apocynin (NAPH oxidase
inhibitor) Mice Warm ischemia 30min ↓ Oxidative stress
TBC-1269 (PAN selectin) Mice Warm ischemia 90min ↓ Inﬂammatory response, ↓ ERK 1/2
Melatonin (hormone) Rat Warm ischemia 40min ↓ I K Ka n dJ N Kp a t h w a y s
Ascorbate (ROS scavenger) Rat Warm ischemia 30min ↓ Apoptosis
FK506
(Immunosuppressant) Rat Warm ischemia 60, 90min ↓ TNF
Gabexate mesilate
(Protease inhibitor) Rat Warm ischemia 60min ↓ Leukocyte activation, ↓ TNFα
OP-2507 (Analogue of
prostacyclin) Rat Warm ischemia 60min ↓ Microcirculatory disturbances
WY-14643 (PPAR-α
agonist) Rat Warm ischemia 60min
↓ Inﬂammatory cytokines, ↓oxidative
stress
α-Lipoic acid (Antioxidant) Rat Warm ischemia 90min ↓ Apoptosis, ↑ liver regeneration
Sirolimus
(Immunossupressant) Rat Warm ischemia +
hepatectomy 60min ↓ Linfocytes
IL-1ra (IL-1 receptor
antagonist) Rat Warm ischemia +
hepatectomy 90min ↓ TNF and oxidative stress
FK 3311 (Cox-2 Inhibitor) Dog Warm ischemia 60min ↓ Cox-2, ↓ neutrophil inﬁltration
for normal and ischemically damaged livers, respectively
[50]. The NMP circuit dually perfuses 1.5L of autologous
heparinized blood at physiological pressures, which allows
hepatic blood ﬂow autoregulation. Prostacyclin, taurocholic
acid, and essential amino acids are infused continuously.
Apart from logistics, one potential drawback of NMP is the
mandatory use of oxygen carriers if blood is not available
[50]. Perhaps the only weakness is that SCS prior to NMP
revokes its beneﬁcial eﬀect. Therefore, immediately after
cardiac asystole, normothermic perfusion in the donor
should be installed, as described by Fondevila et al. [52], for
the preservation of livers from uncontrolled DCD.
The use of non-heart-beating donors (NHBDs) as a
source of liver grafts for transplantation has long been
debated. The concept of normothermic recirculation in
the context of NHBDs was ﬁrst developed by Garc´ ıa-
Valdecasas and Fondevila [53]. With 4h of NMP, hepatic
damage incurred during 90min of cardiac arrest can be
reverted, achieving 100% graft survival after 5 days of
postransplant followup. These results oﬀer the hope that
NMP will be able to increase the clinical applicability of
NHBD LT over that oﬀered by traditional cold storage [53].
5.4. Hypothermic Machine Perfusion. For decades, cooling
down organs to cold temperatures allowed successful organ
transplantation within a limited period. The ﬁrst and
most prominent diﬀerence between SCS and (oxygenated)
hypothermic machine perfusion (HMP) is the restoration
of the tissue’s energy charge and glycogen content while
preventing ATP depletion [50]. In 1990, Pienaar et al. [54]10 Journal of Biomedicine and Biotechnology
reportedthatsevenofeightdogssurvivedafterLTwithHMP
preservationfor72handasimilaroutcomeafter48hofSCS.
There is a substantial body of research, predominantly in
rodents, demonstrating improved preservation by providing
oxygen to livers [55]. Nevertheless, clear guidelines towards
target values/ranges for oxygen levels regarding the optimal
duration of oxygenation during HMP are lacking. HMP can
also be applied at the end of the cold storage period, which is
attractive for logistical reasons. The disadvantage here is the
time-dependent increase in vascular resistance, bearing the
risk of damage to the sinusoidal endothelium [48].
5.5. Subnormothermic Machine Perfusion. Subnormother-
mic machine perfusion (SNMP) preservation lies between
HMP and NMP, but it remained relatively unexplored until
recently despite holding promising applications [56]. In an
isolated rat liver perfusion model, SNMP enhanced the func-
tional integrity of steatotic livers compared with SCS ﬁnd-
ings. Organ-protecting properties mediated by decreasing
thetemperaturetoa20–28◦Cha v ebeenobserv edpr eviously .
SNMP avoids some of the downsides of hypothermia while
maintaining mitochondrial function, and it may circumvent
the logistical restraints of NMP [50].
6. Factors to Be Considered before the Selection
of an ExperimentalModel of HepaticI/R
Many investigators have used rodent models of warm (in
situ) liver I/R to mimic some of the pathophysiological
events that occur during LT. Although a great deal of
useful information has been generated from these studies, an
overriding question remains: Are the mechanisms respon-
sible for transplant-mediated liver injury and dysfunction
the same as those that have been reported for warm liver
I/R injury? The answer is yes and no; that is, some of
the mechanisms are similar, but many are dissimilar. It
is important to make a distinction between the diﬀerent
types of ischemia, because there already is some controversy
regarding the pathophysiological mechanisms depending on
the type of ischemia (cold or normothermic), and it should
be considered that the type of ischemia, the extent and
time of ischemia, the type of liver submitted to I/R, and
the presence of liver regeneration, all lead to diﬀerences in
the pathophysiological mechanisms of hepatic I/R. These
are discussed below to provide the reader with a guide to
select the appropriate experimental model of hepatic I/R
depending on the aims being pursued.
6.1. Relevance of the Duration of Hepatic Ischemia. The
severity of hepatocyte damage depends on duration of
ischemia. Depending on the objectives of the research, it
is important to consider a speciﬁc ischemia duration. In
other words, if you want to study the mechanisms involved
in hepatic I/R injury or the protective mechanisms of a
drug, it is more appropriate to use a duration of ischemia
associated with high survival. If the purpose is to study the
relevance of a drug in hepatic I/R injury, then it is advisable
to assess survival, and, therefore, it is more adequate to
use experimental models in which the ischemic period is
associated with low survival. These observations are based
on the following data reported in the literature. It appears
that short periods (60min) of warm ischemia result in
reversible cell injury, in which liver oxygen consumption
returns to control levels when oxygen is resupplied after
ischemia.Reperfusionaftermoreprolongedperiodsofwarm
ischemia (120–180min) results in irreversible cell damage.
These observations agree with a previous report on rat liver
subjected to I/R, indicating a cellular endpoint for hepato-
cytes after 90min of ischemia [57] .I nh u m a nL T ,al o n g
ischemic period is a predicting factor for posttransplantation
graft dysfunction, and some transplantation groups hesitate
to transplant liver grafts preserved for more than 10h [58].
Some studies in experimental models of LT indicate that
cold ischemia for 24h induces low survival at 24h after LT.
However, LT, following shorter ischemic periods, may also
result in primary organ dysfunction. For animals subjected
to 8h of cold ischemia, an ischemic period associated
with high survival, histological examination of the livers
at 24h after LT revealed multifocal and extensive areas of
hepatocyte coagulative necrosis with neutrophil inﬁltration
and hemorrhage [10, 59].
The mechanisms of hepatic I/R injury are also diﬀerent
depending on the duration of hepatic ischemia. For instance,
toclarifytheimportanceofXDH/XODversusmitochondria,
it should be considered that there are diﬀerences in the
experimental models evaluated, including the duration of
ischemia. Along these lines, XDH/XOD plays a crucial role in
hepatic I/R injury only in conditions under which signiﬁcant
conversion of XDH to XOD occurs (80–90% of XOD) such
as 16h of cold ischemia. However, this ROS generation
system does not appear to be crucial for shorter ischemic
p e r i o d ss u c ha s6ho fc o l di s c h e m i a[ 59]. Thus, even after
prolonged periods of ischemia during which a signiﬁcant
conversion of XDH to XOD occurs, these enzymes may only
play a minor role compared to mitochondria [60]. Similarly,
in assessing the relative contribution of intracellular versus
vascular oxidant stress to hepatic I/R injury, it should also be
notedthatoxidativestressinhepatocytesandthestimulatory
stateofKCsafterI/Rdependonthedurationofischemiaand
may also diﬀer between ischemia at 4◦Ca n dt h a ta t3 7 ◦C,
whichprobablyleadstodiﬀerentdevelopmentalmechanisms
of liver damage [13].
6.2. Relevance of the Extent of Hepatic Ischemia. Another
factor to consider before selecting the experimental model of
hepatic I/R is the percentage of hepatic ischemia applied. It is
known that the extent of hepatic injury as well as the hepatic
I/R mechanisms, including the recovery of blood ﬂow and
energy charge during hepatic reperfusion, is dependent on
the extent of ischemia—whether total or partial (70%)
hepatic ischemia is applied [34, 35]. This fact could be
explained by the stealing phenomenon. In contrast to 100%
hepatic ischemia, during ischemia in the left and median
lobes, the ﬂow is shunted via the right lobes and following
the release of the occlusion of the left and median lobes,
a signiﬁcant amount of shunting via the right lobes willJournal of Biomedicine and Biotechnology 11
continue during reperfusion until vascular resistance in the
postischemic lobes decreases. This occurs because blood
ﬂowsthroughthepathofleastresistance.Thereasonsforthis
may be cellular swelling endothelial, stasis, or other changes.
Thus, the recovery of blood ﬂow and hepatic perfusion of
the preischemic lobe is later in the case of 70% hepatic
ischemia than in 100% hepatic ischemia [61]. In line with
these observations, the beneﬁts of some drugs such as ATP–
MgCl2 were dependent on the extent of hepatic ischemia
used [30, 62].
6.3. Relevance of the Type of Liver Submitted to I/R. A
variety of clinical factors including starvation, graft age, and
steatosis have been studied in diﬀerent experimental models
of hepatic I/R because of the relevance of these factors in
clinical practice. These factors enhance liver susceptibility
to I/R injury, further increasing the patient risks related to
reperfusion injury [13].
6.3.1. Starvation. In clinical LT, starvation of the donor, due
to prolonged intensive care unit hospitalization or the lack
of adequate nutritional support, increases the incidence of
hepatocellular injury and primary nonfunction [63]. Fasting
exacerbates I/R injury because the low content of glycogen
stores results in more rapid ATP depletion during ischemia
[64]. In addition, fasting causes alterations in tissue antiox-
idant defenses, accelerates the conversion of XDH to XOD
during hypoxia and induces mitochondrial alterations [63].
Considering these observations, an artiﬁcial nutritional
support may represent a new approach for the prevention
of reperfusion injury in fasted livers [65]. On the contrary,
fasting has been reported to improve organ viability and
survival [66], as it reduces phagocytosis and the generation
of TNF-α [66]. To understand these apparent contradictory
results, it is important to consider the diﬀerent experimental
conditions in these investigations. A beneﬁcial eﬀect of high
glycogencontentcanmainlybeexpectedunderconditionsof
long preservation times and long periods of warm ischemia.
Under these conditions, high metabolic reserves of the liver
may attenuate ischemic cell injury and preserve defense
functions against cytotoxic mediators of KCs. Conversely,
short ischemic periods require lower metabolic reserves, and
the extent of KC activation can be the dominant factor in
early graft injury [10].
6.3.2. Age. A number of distinct age-related alterations have
been identiﬁed in the hepatic inﬂammatory response to hep-
aticI/R[10,67]. Underwarmhepatic ischemia, mature adult
mice had greatly increased neutrophil function, increased
intracellular oxidant levels, and decreased mitochondrial
function compared with the ﬁndings in young adult mice.
These alterations contributed to the increased liver injury
after I/R observed in mature adult mice compared with that
in young adult mice. The results obtained in an experimen-
tal model of isolated perfused liver indicate that, during
reperfusion, livers obtained from old rats generate a lower
amount of oxyradicals than livers from young rats. This fact
could be explained by the lower KC activity, the reduction of
liver blood ﬂow, and the impaired functions and structural
alterations observed in the livers of old rats [68]. In fact,
in hepatocytes from mature adult mice, delayed activation
o fn u c l e a rf a c t o rk a p p aB( N F κB) in response to TNF-α
and virtually no production of macrophage inﬂammatory
protein 2 have been detected, which may be due to an age-
related defect in hepatocytes [10, 67].
6.3.3. Steatosis. The ﬁrst step to minimize the adverse eﬀects
of I/R in steatotic livers is a full understanding of the
mechanisms involved in I/R injury in these marginal organs
[10]. This can be achieved only with the selection of an
appropriate method to induce steatosis in livers undergoing
I/R. It is well known that the mechanisms involved in
hepatic I/R injury are diﬀerent depending on the type of
liver (nonsteatotic versus steatotic livers). In addition to
the impairment of microcirculation, mitochondrial ROS
generation dramatically increases during reperfusion in
steatoticlivers[69–71].Resultsobtainedunderwarmhepatic
ischemia indicate that apoptosis is the predominant form of
hepatocyte death in the ischemic nonsteatotic liver, whereas
the steatotic livers develop massive necrosis after an ischemic
insult [72]. Steatotic livers diﬀered from nonsteatotic livers
in their response to the unfolded protein response and endo-
plasmic reticulum stress since inositol-requiring enzyme 1
and PKR-like ER kinase were weaker in the presence of
steatosis [73]. Decreased ATP production and dysfunction
of regulators of apoptosis, such that Bcl-2, Bcl-xL and Bax
have been proposed to explain the failure of apoptosis in
steatotic livers. Diﬀerences were also observed when we
analyzed the role of the renin-angiotensin system, as the
nonsteatotic grafts exhibited higher angiotensin (Ang)-II
levels than steatotic grafts whereas steatotic grafts exhibited
higher Ang-(1–7) levels [74]. Moreover, reduced retinol-
binding protein 4 and increased peroxisome proliferator-
activated receptor gamma (PPAR)-γ levels were observed
in steatotic livers compared to nonsteatotic livers [75]. The
vulnerability of steatotic livers subjected to warm ischemia is
also associated with increased adiponectin, oxidative stress,
and IL-1 levels and a reduced ability to generate IL-10 and
PPAR-α [31, 76].
It should be considered that there are diﬀerences in
the mechanisms involved in hepatic I/R injury depending
on the method used to induce steatosis. In contrast with
other experimental models of steatosis, both dietary high fat
and alcohol exposure induced the production of superoxide
dismutase (SOD)/catalase-insensitive ROS, which may be
involved in the mechanism of steatotic liver failure after
OLT [77]. Neutrophils have been involved in the increased
vulnerability of steatotic livers to I/R injury, especially
in alcoholic steatotic livers. However, neutrophils do not
account for the diﬀerentially greater injury in nonalcoholic
steatotic livers during the early or late hours of reperfusion.
Similarly, the role of TNF in the vulnerability of steatotic
livers to I/R injury may be dependent on the type of steatosis
[4, 78].
6.4. Relevance of Regeneration in Experimental Models of
Hepatic I/R. It is known that diﬀerent experimental models12 Journal of Biomedicine and Biotechnology
trigger diﬀerent responses when a common mechanism or
the same drug is investigated. This situation is witnessed
when analyzing liver injury in models of I/R with or without
hepatectomy. This situation is illustrated by Ramalho et al.
[34] regarding the loss of protection of Ang-II receptor
antagonists against liver damage in conditions of partial
hepatectomy under I/R compared with the study of I/R
without hepatectomy, in which Ang-II receptor antagonists
reduced hepatic damage. These diﬀerent results could not
be explained by diﬀerences in the dose or frequency of
drug administration but rather by diﬀerences in surgical
conditions (percentage of hepatic ischemia and the presence
or absence of hepatectomy). In the model of I/R without
hepatectomy [32], the blood supply to the left and median
liver lobes (70% hepatic mass) was interrupted, and the
other hepatic lobes remained intact. However, in partial
hepatectomy under I/R, only blood supply to the remnant
liver (30% hepatic mass) was interrupted and the other
hepatic lobes were excised [34]. It is well known that the
mechanisms of hepatic damage are diﬀerent depending on
the percentage of hepatic mass that is deprived of blood
[10, 61, 62]. In addition, the inherent mechanisms of hepatic
damage derived from the extensive removal of hepatic mass
should be considered [34].
In line with the data above mentioned, ischemic precon-
ditioning (IP) (a surgical strategy that exert beneﬁts in
hepatic I/R) reduced XDH/XOD in nonreduced liver grafts
during cold ischemia [72] whereas IP did not induce
changes in this ROS generating system in reduced-size liver
grafts [46]. In contrast to the conditions of I/R without
hepatectomy [79], hepatic regeneration was not correlated
to the ATP levels of the remaining liver in small-for-size liver
grafts [46]. The reduction in TNF release following hepatic
I/R induced by IP has been previously reported in cold
ischemia conditions without hepatectomy [72]. However, IP
did not modify the levels of TNF in reduced-size liver grafts
after transplantation [46].
7. StrategiesApplied inExperimental
Models of Hepatic I/R
7.1. Pharmacological Treatment. Numerous experimental
studies have focused on the developing pharmacological
strategies aimed at inhibiting the harmful eﬀects of I/R
[13,59,73,76,79–88].Someofthesestudiesaresummarized
in Table 1. However, none of these treatments has managed
to prevent hepatic I/R injury. The possible side eﬀects of
some drugs may frequently limit their use in human LT
[13]. For example, idiosyncratic liver injury in humans
is documented for chlorpromazine, pernicious systemic
eﬀects have been described for NO donors, allopurinol
therapy can cause hematological changes and gadolinium
can induce coagulation disorders [13]. Some case reports
of acute hepatotoxicity attributed to rosiglitazone have been
published [89]. High dose of resveratrol aggravated liver
injury [90]. The development of therapeutic strategies that
utilize the protective eﬀect of heme oxygenase-1 induction is
hampered by the fact that most pharmacological inducers of
this enzyme perturb organ function by themselves [91].
Pharmacological treatment-derived diﬃculties must also
be considered. In this regard, SOD and glutathione exhibit
inadequate delivery to intracellular sites of ROS action [92].
The administration of anti-TNF antibodies does not eﬀec-
tively protect against hepatic I/R injury, and this ﬁnding has
been related to the failure of complete TNF-α neutralization
locally [93]. Although this also occurs in nonsteatotic livers,
modulating I/R injury in steatotic livers poses a greater
problem. Diﬀerences in the action mechanisms between
steatotic and nonsteatotic livers mean that therapies that
are eﬀective in nonsteatotic livers may prove useless in the
presence of steatosis, and the eﬀective drug dose may diﬀer
between the two liver types. Findings such as these must
be considered when applying pharmacological strategies in
the same manner to steatotic and nonsteatotic livers because
the eﬀects may be very diﬀerent. For example, caspase
inhibition, a highly protective strategy in nonsteatotic livers,
had no eﬀect on hepatocyte injury in steatotic livers [70].
Moreover, whereas in an LT experimental model, an NO
donor reduced oxidative stress in nonsteatotic livers, the
same dose increased the vulnerability of steatotic grafts
to I/R injury [94]. Furthermore, there may be drugs that
would only be eﬀective in steatotic livers. This was the
case of compounds such as cerulenin, which reduce UCP-2
expression in steatotic livers [95, 96] and carnitine [97].
Further investigations are required to optimize some
treatments because long-term therapy (more of 10 days)
appearstobenecessarytoexertthedesiredeﬀects[98].How-
ever, there are obvious diﬃculties concerning the feasibility
of long-term drug administration in some I/R processes,
in particular, LT from cadaveric donors, because this is an
emergency procedure in which there is very little time to
pretreat the donor with drugs.
7.2. Preservation Solutions
7.2.1. Additives in Preservation Solutions. The inclusion of
some components in the UW solution has been both
advocated and criticized. For instance, adenosine has been
added to the UW solution as a substrate for the generation of
adenine nucleotides. However, simpliﬁed variants of the UW
solution in which adenosine was omitted were demonstrated
to have similar or even higher protective potential during
cold liver storage. Another limitation of the UW solution
is that some of its constituent compounds (allopurinol,
lactobionate) do not oﬀer very good protection because they
are not present at a suitable concentration and encounter
problems in reaching their site of action [13, 99].
A number of ingredients, which have been summarized
in Table 2, have been introduced into UW solution in
experimental models of hepatic cold ischemia [13, 100–
106]. However, none of these modiﬁcations to the UW
solution composition have found their way into routine
clinical practice. For instance, studies aimed at enriching
the UW solution with caspase inhibitors revealed that this
prevents SEC apoptosis, but such inhibitors have little eﬀectJournal of Biomedicine and Biotechnology 13
Table 2: Additives to UW solution to protect liver against ischemia/reperfusion. Nitric oxide, NO; platelet-activating factor, PAF; sinusoidal
endothelial cells, SEC.
Additives to UW solution
Liver transplantation
Drug Specie Ischemic time Eﬀect
Ruthenium red (mitochondrial
Ca2+ uniporter inhibitor) Rat 24h ↓ Mitocondrial dysfunction
OP-4183 (PGI2 analogue) Rat 24h ↓ Oxidative stress
SAM (ATP precursor) Rat 24h ↓ Oxidative stress
Triﬂuoperazine (calmodulin
inhibitor) Dog 24h
↓ Microcirculatory
dysturbances
Sodium nitroprusside (NO donor) Rat 24, 48h
↓ Microcirculatory
dysturbances
E5880 (PAF antagonist) Pig 8h
↓ Microcirculatory
dysturbances
FR167653 (p38 inhibitor) Rat 30h
↓ Microcirculatory
dysturbances
EGF, IGF-1, NGF-α Pig 18h ↑ ATP
LY294002 (PI3K inhibitor) Rat 3, 7, 9, 24h ↓ Apoptosis
IDN-1965 (caspase inhibitors) Rat 24, 30h ↓ Apoptosis
8br-cAMP and 8br-cGMP
(nucleotide analogs) Rat 24h
↓ NFα and neutrophil
accumulation,
GSNO (NO donor) Rat 48h ↓ SEC damage
Piﬁthrin-alpha (p53 inhibitor) Rat 24, 48h ↓ Apoptosis
OP-4183 (PGI2 analogue) Rat 24h ↓ Oxidative stress
Tauroursodeoxy-cholate Rat 2h
↓ Endoplasmic reticulum
stress
onnecrosis[14].Alongtheselines,theadditionofprecursors
for ATP resynthesis such as S-adenosyl methyltransferase
resulted in poor initial ATP recovery during liver reperfusion
[107].
7.2.2. Use of Perﬂuorochemicals in Preservation Solutions.
Perﬂuorochemicals (PFC) are hydrocarbons, in which all
or most of the hydrogen atoms have been replaced with
ﬂuorine [108]. The most interesting property of PFC is
a very high capacity for dissolving respiratory and other
nonpolar gases. A negligible O2-binding constant of PFC
allows them to release O2 more eﬀectively than hemoglobin
into the surrounding tissue (acts as an oxygen-supplying
agent) [109]. PFC diﬀers from hemoglobin preparations in
that it is a totally synthetic compound formed on a liquid
hydrocarbon base. In contrast to hemoglobin, oxygen is not
chemically bound to the PFC carrier. Unlike hemoglobin,
acidosis, alkalosis, and temperature seem to have no or little
eﬀectontheoxygendeliveryofPFC,allowingthiscompound
to be used eﬀectively during cold storage of organs [110].
Since the 1980s, PFC has been used intravenously as an
“artiﬁcial blood” [111]. Several small animal studies have
reported the beneﬁcial eﬀects of liver perfusion with PFC
emulsions. PFC was ﬁrst used for liver graft preservation in
1980 by Kamada et al. [112] which perfused the livers of rat
with a PFC Fluosol (FC-43)-based solution for up to 25hr,
demonstrating good survival rates after transplantation and
beneﬁcial eﬀect of PFCs [111, 112]. By using a similar rat
model, Tamaki et al. [113] showed that liver perfusion using
a combination of hemaccel-isotonic citrate solution with
FC-43 could prolong liver preservation for up to 48hr. In
another liver rodent model, perfusion with a PFC emulsion
was also found to protect against nonparenchymal cell injury
[114]. Nonetheless, these techniques were not translated
successfully to the porcine liver with a report of increased
intravascularresistanceduringperfusion[115].Inthisreport
theauthorsconcludedthatpossiblecausesrelatedtothehigh
instability of the PFC-based solution, causing complement
activation leading to an increased leucocyte adhesion and
furthermacromoleculesorthattheperfusiontechniqueitself
causedinjury(astrongvasoconstrictioncausedbytheinﬂow
of cold PDF-UW emulsion) [115, 116]. In recenting study,
used oxycyte, a PFC added to UW solution can be beneﬁcial
after cardiac death liver graft preservation in a rat model
[111]. In such study, after cardiac arrest, livers were ﬂushed
and preserved during 8h in preoxygenated UW solution
containing Oxycyte. The authors show that the primary
mechanism of action is due to PFC’s ability to carry high
amounts of O2 along with rapid dissociation in the tissue.
This can help to minimize organ injury after prolonged
hypoxia.ApossiblesecondarymechanismofthisO2 actionis
suppression of hypoxia-induced apoptosis mediated through
a mitochondrial pathway. PFC also appears to activate
downregulation or reversal of gene activation responsible14 Journal of Biomedicine and Biotechnology
Table 3: Gene therapy to protect liver againts ischemia/reperfusion. Heme oxygenase-1, HO-1; interleukin-13, IL-13; small interference
RNA, siRNA; superoxide dismutase, SOD; tumour necrosis factor TNF.
Gene therapy
Liver transplantation and warm hepatic ischemia
Drug Specie Experimental model Ischemic time Eﬀect
Bag-1 (adenoviral transfer) Rat Liver transplantation 24h
↓ TNFα, ↓neutrophil inﬁltration,
↓ microcirculatory disturbances
Bcl-2 gene (adenoviral transfer) Rat Liver transplantation 16h ↓ Apoptosis
Cu/Zn-SOD gene (adenoviral transfer) Rat Liver transplantation 24h ↓ Oxidative stress
HO-1 gene (adenoviral transfer) Rat Liver transplantation 4h
↓ Macrophage inﬁltration, ↓
apoptosis
IL-13 (adenoviral transfer) Rat Liver transplantation 24h
↓ Proinﬂammatory cytokines, ↓
liver neutrophil recruitment
Adiponectin (siRNA) Rat Warm ischemia 1h ↓ Oxidative stress
ASMase (siRNA) Mice Warm ischemia +
hepatectomy 90min ↓ Ceramide, ↓ apoptosis
Caspase 3 (siRNA) Mice Warm ischemia 90min ↓ Apoptosis
Caspase 8 (siRNA) Mice Warm ischemia 90min ↓ Apoptosis
SOD gene (adenoviral transfer) Rat Warm ischemia 1h ↓ Oxidative stress
IL-13 (adenoviral transfer) Rat Warm ischemia 30min
↓ Proinﬂammatory cytokine, ↓
neutrophil recruitment
for apoptosis [111]. Although the beneﬁts of preoxygenated
P F Ch a v eb e e nr e p o r t e do nl i v e rp r e s e r v a t i o n ,t h e i re ﬀects
on reperfusion injury were not evaluated in that study. In
fact, the possibility that preoxygenated PFC exacerbates the
reactive oxygen species during reperfusion should not be
discarded. In fact, previous studies indicate that the use
of gaseous oxygen, applied to the livers during the storage
period via the caval vein was only eﬀective in improving
hepatic viability upon reperfusion when antioxidants were
added to the UW rinse solution [117].
7.3. Gene Therapy. Advances in molecular biology have
provided new opportunities to reduce liver I/R injury
using gene therapy [13, 14, 31, 80, 118–120] (see Table 3).
However, the experimental data indicate that there are a
number of problems inherent in gene therapy, such as vector
toxicity, diﬃculties in increasing transfection eﬃciencies
and protein expression at the appropriate time and site,
and the problem of obtaining adequate mutants (in the
case of NFκB) due to the controversy regarding NFκB
activation [121, 122]. Although nonviral vectors (such as
naked DNA and liposomes) are likely to present fewer toxic
orimmunologicalproblems,theysuﬀerfromineﬃcientgene
transfer [122]. In addition, LT is an emergency procedure in
most cases, which leaves very little time to pretreat the donor
with genetic approaches.
7.4. Surgical Strategies. T h er e s p o n s eo fh e p a t o c y t et o
ischemia never ceases to surprise. In fact, contrary to what
might be expected, the induction of consecutive periods of
ischemia in the liver does not induce an additive eﬀect in
terms of hepatocyte lesions. IP based on brief periods of
ischemia followed by a short interval of reperfusion prior
to a prolonged ischemic stress protects the liver against
I/R injury by regulating diﬀerent cell types and multiple
mechanisms such as energy metabolism, microcirculatory
disturbances, leukocyte adhesion, KC activation, proinﬂam-
matory cytokine release, oxidative stress, apoptosis, and
necrosis [13, 80]( Table 4). This is an advantage in relation
with the use of drugs that exerts its action on a speciﬁc
mechanism.
The beneﬁts of IP observed in experimental models of
hepatic warm and cold ischemia [80, 123]p r o m p t e dh u m a n
trialsofIP.Todate,IPhasbeensuccessfullyappliedinhuman
liver resections in both steatotic and nonsteatotic livers. The
eﬀectiveness of IP in hepatic surgery was ﬁrst reported by
Clavien et al. in 2003 [124], preliminary clinical studies have
reported the beneﬁts of IP in LT [125, 126], and additional
randomizedclinicalstudiesarenecessarytoconﬁrmwhether
this surgical strategy can be commonly used in clinical liver
surgery.
8. Conclusion andPerspectives
From the data obtained in experimental models of hepatic
I/R, we can state that I/R injury is a multifaceted and
intriguing phenomenon that probably cannot be reduced
to a single pathway. The increasing use of marginal donors
in major liver surgery and the fact that these organs are
more susceptible to ischemia highlight the need for further
research directed at the mechanisms of I/R injury. However,
the mechanisms by which metabolic changes due to age
or steatosis aﬀect I/R injury and subsequently inﬂuence
protective strategies are poorly understood. Whether liver
machine perfusion will ﬁnd its way into widespread clinical
application remains uncertain. Machine perfusion has been
criticized for its complicated logistics (e.g., portability) and
for possibly damaging the organ and vital structures such asJournal of Biomedicine and Biotechnology 15
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theendothelium.Onthecontrary,NMPfulﬁlsallidealorgan
preservation criteria by avoiding hypoxia and hypothermia.
Responses to the strategies aimed at reducing hepatic I/R
injury might depend on the surgical procedure and type
of liver. Whether the pharmacological approaches presented
in this review can be translated into treatments for human
disease remains unknown, but further research is required
to optimize the treatments. Surgical strategies such as IP
aﬀect multiple aspects of IR injury, whereas pharmacological
approaches often aﬀect only a few mediators and might have
systemic side eﬀects. Only a full appraisal of the mechanisms
involved in hepatic I/R using experimental models will
permit the design of new protective strategies in clinical liver
surgery.
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